Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Nextech3D.AI Announces Increase in Revenue Growth for Arway with Map D Acquisition (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Allarity Therapeutics Inc ALLR

Healthcare Biotechnology
Allarity Therapeutics, Inc. is a clinical-stage pharmaceutical company focused on developing personalized cancer treatments. The Company is focused on development of stenoparib, a poly-ADP-ribose polymerase/Tankyrase inhibitor for advanced ovarian cancer patients, using its DRP companion diagnostic for patient selection in the ongoing phase 2 clinical trial, NCT03878849. It has in-licensed the... see more

Recent & Breaking News (NDAQ:ALLR)

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALLR

Newsfile August 22, 2024

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. for potential violations of federal securities laws

ACCESS Newswire August 22, 2024

ROSEN, A RANKED AND LEADING FIRM, Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALLR

Newsfile August 21, 2024

Rosen Law Firm Encourages Allarity Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - ALLR

PR Newswire August 19, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

ACCESS Newswire August 19, 2024

Allarity Therapeutics Is Being Investigated By The Schall Law Firm For Securities Law Violations And Encourages Shareholders To Join

ACCESS Newswire August 19, 2024

Wolf Haldenstein Adler Freeman & Herz LLP Announces that it is Investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for Potential Violations of Federal Securities Laws

ACCESS Newswire August 19, 2024

The Schall Law Firm Is Investigating Allarity Therapeutics For Securities Fraud And Invites Investors To Join

ACCESS Newswire August 18, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

PR Newswire August 17, 2024

The Schall Law Firm Is Looking Into Allarity Therapeutics For Securities Fraud And Encourages Shareholders To Join

ACCESS Newswire August 17, 2024

The Schall Law Firm Is Investigating Allarity Therapeutics For Securities Fraud And Invites Investors To Join

ACCESS Newswire August 16, 2024

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws

ACCESS Newswire August 16, 2024

The Schall Law Firm's Allarity Therapeutics Inc Securities Fraud Investigation Is Open For ALLR Investors

ACCESS Newswire August 15, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

ACCESS Newswire August 15, 2024

The Schall Law Firm's Allarity Therapeutics Inc Securities Fraud Investigation Is Available For ALLR Investors

ACCESS Newswire August 14, 2024

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. (NASDAQ: ALLR) for potential violations of federal securities laws

PR Newswire August 14, 2024

Wolf Haldenstein Adler Freeman & Herz LLP announces that it is investigating Allarity Therapeutics, Inc. for potential violations of federal securities laws

ACCESS Newswire August 14, 2024

Allarity Therapeutics Inc Securities Fraud Investigation By The Schall Law Firm Is Open For ALLR Investors

ACCESS Newswire August 13, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Allarity Therapeutics, Inc. - ALLR

ACCESS Newswire August 13, 2024

The Schall Law Firm Opens Securities Fraud Investigation Into Allarity Therapeutics Inc For ALLR Investors

ACCESS Newswire August 12, 2024